{
    "clinical_study": {
        "@rank": "40046", 
        "arm_group": {
            "arm_group_label": "E7080", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This study is to evaluate the safety, efficacy, and pharmacokinetics of E7080 when orally\n      administered once daily (QD) in subjects with advanced thyroid cancer."
        }, 
        "brief_title": "A Study of E7080 in Subjects With Advanced Thyroid Cancer", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Thyroid Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Thyroid Neoplasms", 
                "Thyroid Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria\n\n          1. Histologically or clinically diagnosed with thyroid cancer\n\n          2. Eastern Cooperative Oncology Group Performance Status (ECOG-PS) 0-2\n\n          3. Adequate laboratory values/organ function tests\n\n        Exclusion criteria\n\n        Subjects with following complication or disease history\n\n          1. Brain metastasis\n\n          2. Systemic severe infection\n\n          3. Significant cardiovascular impairment\n\n          4. QTc greater than 480 milliseconds\n\n          5. Active hemoptysis\n\n          6. Bleeding or thrombotic disorders\n\n          7. Having greater than 1+ proteinuria on urine dipstick testing will undergo 24 hr urine\n             collection for quantitative assessment of proteiuria\n\n          8. Gastrointestinal malabsorption or any other condition in the opinion of the\n             investigator that might affect the absorption of E7080\n\n          9. Major surgery within 3 weeks before enrollment\n\n         10. With co-existing effusion requiring drainage"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 7, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01728623", 
            "org_study_id": "E7080-J081-208"
        }, 
        "intervention": {
            "arm_group_label": "E7080", 
            "description": "E7080 is administered as continuous once daily dosing in an uncontrolled manner", 
            "intervention_name": "E7080 capsule", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Thyroid cancer", 
        "lastchanged_date": "February 20, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Kashiwa", 
                        "country": "Japan", 
                        "state": "Chiba"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kobe", 
                        "country": "Japan", 
                        "state": "Hyogo"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Koto-ward", 
                        "country": "Japan", 
                        "state": "Tokyo"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 2 Study of E7080 in Subjects With Advanced Thyroid Cancer", 
        "overall_contact": {
            "email": "_ML_CLNCL@hhc.eisai.co.jp", 
            "last_name": "Department of customer Joy, EJ"
        }, 
        "overall_official": {
            "affiliation": "Oncology Clinical Development Section, Japan / Asia Clinical Research, Product Creation Unit, Eisai Product Creation System", 
            "last_name": "Tatsuya Sasaki", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of Participants with Non-Serious Adverse Events and Serious Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Change from baseline in hematology, blood biochemistry, urinalysis, vital signs, ECG, physical test data", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01728623"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "From Study Start until progression of disease or date of death from any cause, whichever comes first, assessed up to 40 months"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "From Study Start until date of death from any cause, assessed up to 40 months"
            }
        ], 
        "source": "Eisai Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eisai Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}